Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative fluorescence imaging with bevacizumab-IRDye 800CW for perihilar cholangiocarcinoma
NL-OMON46827Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab-IRDye800CW in hilar cholangiocarcinoma (HC) and cholangiocarcinoma (CCA) (3 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Histopathologic confirmation of higher tumor fluorescence, Tumor-to-background ratio and 2 more. Started May 2018; status: recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
hilar cholangiocarcinoma (HC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON46827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46827.